Tissue-based molecular markers for renal cell carcinoma

M. Rink, F. K H Chun, B. Robinson, M. Sun, P. I. Karakiewicz, K. Bensalah, M. Fisch, D. S. Scherr, R. K. Lee, V. Margulis, S. F. Shariat

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Since the introduction of targeted therapies in renal cell carcinoma (RCC), more individualized treatment options have become available. Molecular markers might support treatment planning due to more accurate individual risk stratification. Current molecular markers in RCC were reviewed to elucidate clinical impact and future perspectives. An English-language literature review of the Medline database (1990 to September 2010) of published data on tissue-based molecular markers and RCC was undertaken. Histological types, clinical and oncological behaviour are variable in renal masses. Molecular markers offer potential for additional information in tumour detection and diagnosis, prognostic and predictive values, as well as determination of therapeutic targets. Investigations on molecular biomarkers in RCC include hypoxia inducible factor (HIF-α), vascular endothelial growth factor (VEGF), carbonic anhydrase IX (CAIX), mammalian target of rapamycin (mTOR), survivin, B7-H1, p53, matrix metalloproteinases (MMP), Insulin-like growth factor II mRNA-binding protein 3 (IMP3), Ki-67, C-reactive protein (CRP), Vimentin, Fascin, platelet count, hemoglobin level and combinations of these factors. Although some markers offer promising results, utilization in daily practice is compromised due to limited specificity, predictive accuracy and tumour histology variablity. There is an imminent need for novel molecular markers that allow accurate histologic and biologic classification of RCC to improve upon current outcomes. It is very likely that a panel of molecular markers will be used to achieve a sufficient degree of certainty in order to guide clinical decisions. A large concerted effort is required to advance the field of RCC molecular marker through systematic discovery, verification, and validation.

Original languageEnglish (US)
Pages (from-to)293-308
Number of pages16
JournalMinerva Urologica e Nefrologica
Volume63
Issue number4
StatePublished - Dec 2011

Fingerprint

Renal Cell Carcinoma
Insulin-Like Growth Factor II
Vimentin
Sirolimus
Therapeutics
Matrix Metalloproteinases
Platelet Count
C-Reactive Protein
Vascular Endothelial Growth Factor A
Neoplasms
Histology
Carrier Proteins
Hemoglobins
Language
Biomarkers
Databases
Kidney
Messenger RNA

Keywords

  • Biological markers
  • Carcinoma, renal cell
  • Diagnosis
  • Immunohistochemistry
  • Neoplasm staging
  • Prognosis

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Rink, M., Chun, F. K. H., Robinson, B., Sun, M., Karakiewicz, P. I., Bensalah, K., ... Shariat, S. F. (2011). Tissue-based molecular markers for renal cell carcinoma. Minerva Urologica e Nefrologica, 63(4), 293-308.

Tissue-based molecular markers for renal cell carcinoma. / Rink, M.; Chun, F. K H; Robinson, B.; Sun, M.; Karakiewicz, P. I.; Bensalah, K.; Fisch, M.; Scherr, D. S.; Lee, R. K.; Margulis, V.; Shariat, S. F.

In: Minerva Urologica e Nefrologica, Vol. 63, No. 4, 12.2011, p. 293-308.

Research output: Contribution to journalArticle

Rink, M, Chun, FKH, Robinson, B, Sun, M, Karakiewicz, PI, Bensalah, K, Fisch, M, Scherr, DS, Lee, RK, Margulis, V & Shariat, SF 2011, 'Tissue-based molecular markers for renal cell carcinoma', Minerva Urologica e Nefrologica, vol. 63, no. 4, pp. 293-308.
Rink M, Chun FKH, Robinson B, Sun M, Karakiewicz PI, Bensalah K et al. Tissue-based molecular markers for renal cell carcinoma. Minerva Urologica e Nefrologica. 2011 Dec;63(4):293-308.
Rink, M. ; Chun, F. K H ; Robinson, B. ; Sun, M. ; Karakiewicz, P. I. ; Bensalah, K. ; Fisch, M. ; Scherr, D. S. ; Lee, R. K. ; Margulis, V. ; Shariat, S. F. / Tissue-based molecular markers for renal cell carcinoma. In: Minerva Urologica e Nefrologica. 2011 ; Vol. 63, No. 4. pp. 293-308.
@article{2176e265171344fba4fd8f28b0712650,
title = "Tissue-based molecular markers for renal cell carcinoma",
abstract = "Since the introduction of targeted therapies in renal cell carcinoma (RCC), more individualized treatment options have become available. Molecular markers might support treatment planning due to more accurate individual risk stratification. Current molecular markers in RCC were reviewed to elucidate clinical impact and future perspectives. An English-language literature review of the Medline database (1990 to September 2010) of published data on tissue-based molecular markers and RCC was undertaken. Histological types, clinical and oncological behaviour are variable in renal masses. Molecular markers offer potential for additional information in tumour detection and diagnosis, prognostic and predictive values, as well as determination of therapeutic targets. Investigations on molecular biomarkers in RCC include hypoxia inducible factor (HIF-α), vascular endothelial growth factor (VEGF), carbonic anhydrase IX (CAIX), mammalian target of rapamycin (mTOR), survivin, B7-H1, p53, matrix metalloproteinases (MMP), Insulin-like growth factor II mRNA-binding protein 3 (IMP3), Ki-67, C-reactive protein (CRP), Vimentin, Fascin, platelet count, hemoglobin level and combinations of these factors. Although some markers offer promising results, utilization in daily practice is compromised due to limited specificity, predictive accuracy and tumour histology variablity. There is an imminent need for novel molecular markers that allow accurate histologic and biologic classification of RCC to improve upon current outcomes. It is very likely that a panel of molecular markers will be used to achieve a sufficient degree of certainty in order to guide clinical decisions. A large concerted effort is required to advance the field of RCC molecular marker through systematic discovery, verification, and validation.",
keywords = "Biological markers, Carcinoma, renal cell, Diagnosis, Immunohistochemistry, Neoplasm staging, Prognosis",
author = "M. Rink and Chun, {F. K H} and B. Robinson and M. Sun and Karakiewicz, {P. I.} and K. Bensalah and M. Fisch and Scherr, {D. S.} and Lee, {R. K.} and V. Margulis and Shariat, {S. F.}",
year = "2011",
month = "12",
language = "English (US)",
volume = "63",
pages = "293--308",
journal = "Minerva Urologica e Nefrologica",
issn = "0393-2249",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Tissue-based molecular markers for renal cell carcinoma

AU - Rink, M.

AU - Chun, F. K H

AU - Robinson, B.

AU - Sun, M.

AU - Karakiewicz, P. I.

AU - Bensalah, K.

AU - Fisch, M.

AU - Scherr, D. S.

AU - Lee, R. K.

AU - Margulis, V.

AU - Shariat, S. F.

PY - 2011/12

Y1 - 2011/12

N2 - Since the introduction of targeted therapies in renal cell carcinoma (RCC), more individualized treatment options have become available. Molecular markers might support treatment planning due to more accurate individual risk stratification. Current molecular markers in RCC were reviewed to elucidate clinical impact and future perspectives. An English-language literature review of the Medline database (1990 to September 2010) of published data on tissue-based molecular markers and RCC was undertaken. Histological types, clinical and oncological behaviour are variable in renal masses. Molecular markers offer potential for additional information in tumour detection and diagnosis, prognostic and predictive values, as well as determination of therapeutic targets. Investigations on molecular biomarkers in RCC include hypoxia inducible factor (HIF-α), vascular endothelial growth factor (VEGF), carbonic anhydrase IX (CAIX), mammalian target of rapamycin (mTOR), survivin, B7-H1, p53, matrix metalloproteinases (MMP), Insulin-like growth factor II mRNA-binding protein 3 (IMP3), Ki-67, C-reactive protein (CRP), Vimentin, Fascin, platelet count, hemoglobin level and combinations of these factors. Although some markers offer promising results, utilization in daily practice is compromised due to limited specificity, predictive accuracy and tumour histology variablity. There is an imminent need for novel molecular markers that allow accurate histologic and biologic classification of RCC to improve upon current outcomes. It is very likely that a panel of molecular markers will be used to achieve a sufficient degree of certainty in order to guide clinical decisions. A large concerted effort is required to advance the field of RCC molecular marker through systematic discovery, verification, and validation.

AB - Since the introduction of targeted therapies in renal cell carcinoma (RCC), more individualized treatment options have become available. Molecular markers might support treatment planning due to more accurate individual risk stratification. Current molecular markers in RCC were reviewed to elucidate clinical impact and future perspectives. An English-language literature review of the Medline database (1990 to September 2010) of published data on tissue-based molecular markers and RCC was undertaken. Histological types, clinical and oncological behaviour are variable in renal masses. Molecular markers offer potential for additional information in tumour detection and diagnosis, prognostic and predictive values, as well as determination of therapeutic targets. Investigations on molecular biomarkers in RCC include hypoxia inducible factor (HIF-α), vascular endothelial growth factor (VEGF), carbonic anhydrase IX (CAIX), mammalian target of rapamycin (mTOR), survivin, B7-H1, p53, matrix metalloproteinases (MMP), Insulin-like growth factor II mRNA-binding protein 3 (IMP3), Ki-67, C-reactive protein (CRP), Vimentin, Fascin, platelet count, hemoglobin level and combinations of these factors. Although some markers offer promising results, utilization in daily practice is compromised due to limited specificity, predictive accuracy and tumour histology variablity. There is an imminent need for novel molecular markers that allow accurate histologic and biologic classification of RCC to improve upon current outcomes. It is very likely that a panel of molecular markers will be used to achieve a sufficient degree of certainty in order to guide clinical decisions. A large concerted effort is required to advance the field of RCC molecular marker through systematic discovery, verification, and validation.

KW - Biological markers

KW - Carcinoma, renal cell

KW - Diagnosis

KW - Immunohistochemistry

KW - Neoplasm staging

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=83755196223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83755196223&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 293

EP - 308

JO - Minerva Urologica e Nefrologica

JF - Minerva Urologica e Nefrologica

SN - 0393-2249

IS - 4

ER -